Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer

被引:0
|
作者
Mantz, CA
Vokes, EE
Stenson, K
Kies, MS
Mittal, B
Witt, ME
List, MA
Weichselbaum, RR
Haraf, DJ
机构
[1] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Surg, Chicago, IL 60637 USA
[4] Univ Chicago, Ctr Canc Res, Chicago, IL 60637 USA
[5] Northwestern Univ, Dept Radiat Oncol, Chicago, IL 60611 USA
[6] Northwestern Univ, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA
来源
CANCER JOURNAL | 2001年 / 7卷 / 02期
关键词
oropharyngeal cancer; chemoradiotherapy; chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Locoregionally advanced oropharyngeal cancer has been conventionally treated with either surgery and adjuvant radiotherapy or radiotherapy alone, and clinical and functional outcomes have been pear. Chemoradiotherapy has been demonstrated to improve functional outcome and disease control over conventional treatment in recent randomized head and neck trials. Herein, we report overall survival, progression-free survival, and patterns of failure in locoregionally advanced oropharyngeal cancer treated with induction chemotherapy with or without conservative surgery followed by concomitant chemoradiation. MATERIALS AND METHODS Three cycles of induction chemotherapy consisting of cisplatin, 5-fluorouracil, leucovorin, and interferon alpha -2b (PFL-IFN) were followed by conservative, organ-sparing surgery for residual disease. All patients then proceeded to concomitant chemoradiation consisting of seven or eight cycles of 5-fluorouracil, hydroxyurea, and a total radiotherapy dose of roughly 7000 cGy. RESULTS Sixty-one patients with predominantly stage IV disease were treated. Clinical complete response was observed in 65% of patients after induction therapy. The median follow-up was 68.0 months for survivors and 39.0 months for all patients. At 5 years, overall survival is 51%, progression-free survival is 64%, locoregional control is 70%, and distant control is 89%. Locoregional recurrence accounted far 80% of all initial failures. Only five radical surgeries (none were total glossectomy) were performed for initial disease control. Treatment-related toxicity accounted for four deaths. CONCLUSION PR-IFN given with 5-fluorouracil, hydroxyurea, and radiotherapy produces a high rate of cures with organ preservation in a disease group that has traditionally fared poorly. Local and distant disease control and survival rates exceed those observed with more standard treatment approaches involving surgery and radiotherapy. Further investigation into chemoradiotherapy as a curative modality for this disease is warranted.
引用
收藏
页码:140 / 148
页数:9
相关论文
共 50 条
  • [21] Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma?
    He, Yan
    Guo, Tao
    Wang, Jingjing
    Sun, Yu
    Guan, Hui
    Wu, Shaoyong
    Peng, Xingchen
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (05)
  • [22] Induction chemotherapy in head and neck cancer patients followed by concomitant docetaxel-based radiochemotherapy
    Mencoboni, M.
    Grillo-Ruggieri, F.
    Salami, A.
    Scasso, F.
    Rebella, L.
    Grimaldi, A.
    Dellepiane, M.
    Moratti, G.
    Bruzzone, A.
    Spigno, F.
    Ghio, R.
    Figliomeni, M.
    EUROPEAN JOURNAL OF CANCER CARE, 2011, 20 (04) : 503 - 507
  • [23] Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy Outcome in patients with locally advanced head and neck cancer
    Broemme, J. O.
    Schmuecking, M.
    Arnold, A.
    Giger, R.
    Rauch, D.
    Leiser, D.
    Plasswilm, L.
    Geretschlaeger, A.
    Ghadjar, P.
    Aebersold, D. M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 (08) : 618 - 624
  • [24] A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer
    Hitt, R.
    Grau, J. J.
    Lopez-Pousa, A.
    Berrocal, A.
    Garcia-Giron, C.
    Irigoyen, A.
    Sastre, J.
    Martinez-Trufero, J.
    Brandariz Castelo, J. A.
    Verger, E.
    Cruz-Hernandez, J. J.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 216 - 225
  • [25] Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure
    Xing-Li Yang
    Lu-Lu Zhang
    Jia Kou
    Guan-Qun Zhou
    Chen-Fei Wu
    Ying Sun
    Li Lin
    BMC Cancer, 22
  • [26] Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure
    Yang, Xing-Li
    Zhang, Lu-Lu
    Kou, Jia
    Zhou, Guan-Qun
    Wu, Chen-Fei
    Sun, Ying
    Lin, Li
    BMC CANCER, 2022, 22 (01)
  • [27] Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
    Haddad, Robert
    O'Neill, Anne
    Rabinowits, Guilherme
    Tishler, Roy
    Khuri, Fadlo
    Adkins, Douglas
    Clark, Joseph
    Sarlis, Nicholas
    Lorch, Jochen
    Beitler, Jonathan J.
    Limaye, Sewanti
    Riley, Sarah
    Posner, Marshall
    LANCET ONCOLOGY, 2013, 14 (03): : 257 - 264
  • [28] Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers
    Maemura, Kosei
    Mataki, Yuko
    Kurahara, Hiroshi
    Kawasaki, Yota
    Iino, Satoshi
    Sakoda, Masahiko
    Uchikado, Yasuto
    Arigami, Takaaki
    Uenosono, Yoshikazu
    Mori, Shinichiro
    Ueno, Shinichi
    Shinchi, Hiroyuki
    Natsugoe, Shoji
    ANTICANCER RESEARCH, 2017, 37 (01) : 233 - 237
  • [29] Induction Chemotherapy Plus Concurrent Chemoradiotherapy versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis
    Li, Yang
    Tang, Lin-Quan
    Liu, Li-Ting
    Guo, Shan-Shan
    Liang, Yu-Jing
    Sun, Xue-Song
    Tang, Qing-Nan
    Bei, Jin-Xin
    Tan, Jing
    Chen, Shuai
    Ma, Jun
    Zhao, Chong
    Chen, Qiu-Yan
    Mai, Hai-Qiang
    CANCER RESEARCH AND TREATMENT, 2018, 50 (04): : 1304 - 1315
  • [30] Concomitant chemoradiotherapy followed by adjuvant chemotherapy in parotid gland undifferentiated carcinoma
    Airoldi, M
    Gabriele, AM
    Gabriele, P
    Pedani, F
    Marchionatti, S
    Succo, G
    Beatrice, F
    Bumma, C
    TUMORI, 2001, 87 (01) : 14 - 17